Which Complement Inhibitors are available?

This directory covers 2: Soliris, Ultomiris.

Complement Inhibitors

Also called C5 inhibitors, terminal complement blockers

The complement system is part of innate immunity — a cascade of proteins that punches holes in cells marked for destruction. In a handful of rare diseases it turns on the body's own red blood cells, nerves or kidneys. Complement inhibitors block the cascade at C5, before the damaging final step. They are transformative in these conditions, and they raise the risk of meningococcal infection, so vaccination beforehand is mandatory.

What this class is used for

Paroxysmal nocturnal haemoglobinuria (PNH), atypical HUS, myasthenia gravis, NMOSD

2 Complement Inhibitors in this directory

Soliris

Eculizumab

An intravenous biological therapy used to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Ultomiris

Ravulizumab

An intravenous biological therapy administered every 8 weeks to treat rare blood and neurological disorders.

Compare Complement Inhibitors side by side

Soliris VS Ultomiris

Browse other drug classes

ARBs Anti-amyloid Antibodies Antibiotics Antibody-drug Conjugates Anticoagulants Anticonvulsants Antihistamines Antiplatelets Asthma & COPD Inhalers Atypical Antipsychotics BTK Inhibitors Beta Blockers CD20 Antibodies CDK4/6 Inhibitors CGRP Inhibitors COVID-19 Antivirals Checkpoint Inhibitors Cholinesterase Inhibitors DPP-4 Inhibitors EGFR Inhibitors Enzyme Replacement Therapy GLP-1 Agonists Gene & Cell Therapies HIV Antiretrovirals Hepatitis C Antivirals IL-1 Inhibitors IL-17 Inhibitors IL-23 Inhibitors IL-5 Inhibitors IL-6 Inhibitors Insulins JAK Inhibitors PARP Inhibitors PCSK9 Inhibitors Proton Pump Inhibitors SGLT2 Inhibitors SSRIs & SNRIs Statins TNF Inhibitors TTR Silencers Tyrosine Kinase Inhibitors

Class descriptions are written by the Priya Life Science editorial team. Individual drug pages combine that summary with live label, approval, manufacturer and shortage data from the U.S. FDA via the openFDA API. This page is general information and is not medical advice — it is not exhaustive, drugs within a class are not automatically interchangeable, and approvals and brand names differ between the US, EU/Ireland (EMA/HPRA) and other regions. Always consult the official prescribing information and your clinician or pharmacist. Related: Drug Shortages Tracker · FDA Approvals · All drug comparisons